Cited by 710Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsGenetic factors in colorectal cancer

The DOI matches its Crossref record, with a small difference in title or year; 24 of the 24 references it cites were found in a registry or an index.

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials

Open access

Tejpar, Sabine, Stintzing, Sebastian, Ciardiello, Fortunato, Tabernero, Josep, Van Cutsem, Eric, Beier, Frank, Esser, Regina, Lenz, Heinz-Josef, Heinemann, Volker·2017·JAMA Oncology

DOI 10.1001/jamaoncol.2016.3797PMC PMC7505121

Open this paper in CoChat — free account

Abstract

IMPORTANCE: Metastatic colorectal cancer (mCRC) is heterogeneous, and primary tumors arising from different regions of the colon are clinically and molecularly distinct. OBJECTIVE: To examine the prognostic and predictive value of primary tumor location in patients with RAS wild-type (wt) mCRC treated with first-line fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab in the Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL) trial and FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab as First-Line Treatment For Patients With Metastatic Colorectal Cancer (FIRE-3) trial. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective analysis patients with RAS wt metastatic colorectal cancer from the CRYSTAL and FIRE-3 trials were classified as having left-sided or right-sided mCRC, defined, respectively, as patients whose tumors originated in the splenic flexure, descending colon, sigmoid colon, or rectum vs appendix, cecum, ascending colon, hepatic flexure, or transverse colon. MAIN OUTCOMES AND MEASURES: Progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were assessed according to tumor location and treatment arm. RESULTS: In the RAS wt populations of the CRYSTAL and FIRE-3 trials, patients with left-sided tumors (n = 142 and n = 157, respectively) had markedly superior PFS, OS, and ORR compared with patients with right-sided tumors (n = 33 and n = 38, respectively). Among CRYSTAL and FIRE-3 study patients with RAS wt left-sided tumors, FOLFIRI plus cetuximab significantly improved OS relative to the respective comparators (FOLFIRI and FOLFIRI plus bevacizumab); in contrast, in RAS wt patients with poor-prognosis right-sided tumors, limited efficacy benefits were observed upon the addition of cetuximab to FOLFIRI in CRYSTAL, and comparable outcomes were observed between the FOLFIRI plus cetuximab and FOLFIRI plus bevacizumab arms of FIRE-3. A significant interaction was observed between primary tumor location and treatment for OS (CRYSTAL: hazard ratio [HR], 1.95; 95% CI, 1.09-3.48 and FIRE-3: HR, 0.40; 95% CI, 0.23-0.70) within the RAS wt populations of both studies in multivariable models that also included sex, prior adjuvant therapy, and BRAF mutational status. CONCLUSIONS AND RELEVANCE: In the RAS wt populations of CRYSTAL and FIRE-3, patients with left-sided tumors had a markedly better prognosis than those with right-sided tumors. First-line FOLFIRI plus cetuximab clearly benefitted patients with left-sided tumors (vs FOLFIRI or FOLFIRI plus bevacizumab, respectively), whereas patients with right-sided tumors derived limited benefit from standard treatments. TRIAL REGISTRATION: clinicaltrials.gov Identifiers: CRYSTAL, NCT00154102, and FIRE-3, NCT00433927.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2016.3797

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citation
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Self-citation
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Self-citation
FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First-Line Treatment for Patients with Metastatic Colorectal Cancer (FIRE-3): A Randomised, Open-Label, Phase 3 Trial
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Self-citation
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer
Van Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
Self-citation
The Pan-ErbB Negative Regulator Lrig1 Is an Intestinal Stem Cell Marker that Functions as a Tumor Suppressor
Powell, A. E., Wang, Y., Li, Y., Poulin, E. J., Means, A. L., Washington, M. K., Higginbotham, J. N., Juchheim, A., Prasad, N., Levy, S. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.042 · Cited by 694
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
Missiaglia, E., Jacobs, B., D’Ario, G., Narzo, A. F. D., Soneson, C., Budínská, E., Popovici, V. C., Vecchione, L., Gerster, S., Yan, P., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu275 · Cited by 646
Self-citation
Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
Loupakis, F., Yang, D., Yau, L., Feng, S., Cremolini, C., Zhang, W., Maus, M. K. H., Antoniotti, C., Langer, C., Scherer, S. J., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju427 · Cited by 477
Self-citation
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17
Brule, S. Y., Jonker, D. J., Karapetis, C. S., O’Callaghan, C. J., Moore, M. J., Wong, R. P. W., Tebbutt, N. C., Underhill, C. R., Yip, D., Zalcberg, J. R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.03.015 · Cited by 335

Show all 24 references

Sorted by citations

Items 501–600 of 710

[Value of combined detection of ITGA4 and SFRP2 gene methylation in stool DNA in diagnosis and prognostic evaluation of colorectal tumors].
Jin, H., Pang, L., Li, H., Xu, M., Yan, H.-X. W., & Li, R. (2021) · PubMed Central · doi:10.12122/j.issn.1673-4254.2021.06.12 · Cited by 3
Improvement in colorectal cancer outcomes over time is limited to patients with left-sided disease
Rumpold, H. F., Hackl, M., Petzer, A., & Wolf, D. G. F. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03868-0 · Cited by 3
Primary tumor resection with or without metastasectomy for left- and right-sided stage IV colorectal cancer: an instrumental variable analysis
Yao, Y.-C., Chen, J.-Q., Yin, L., Lin, W., Peng, J., & Fan, W. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02184-2 · Cited by 3
Role of family history and tumor location on prognosis of patients with colorectal cancer and synchronous metastases
Colloca, G. A., & Venturino, A. (2017) · International Journal of Colorectal Disease · doi:10.1007/s00384-017-2831-7 · Cited by 3
Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy
Takada, S., Sagawa, T., Fujikawa, K., Tahatsu, K., Fukai, Y., Hashishita, H., Takahashi, Y., & Endo, M. (2018) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2018.19.8.2325 · Cited by 3
Predictive Biomarkers for Monoclonal Antibody Therapies Targeting EGFR (Cetuximab, Panitumumab) in the Treatment of Metastatic Colorectal Cancer
Sakthianandeswaren, A., Sabljak, P., Elliott, M. J., Palmieri, M., & Sieber, O. M. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.80690 · Cited by 3
Efficacy of Neoadjuvant Chemotherapy with Capecitabine plus Oxaliplatin in the Treatment of Locally Advanced Sigmoid Colon Cancer Invading the Urinary Bladder: A Report of Three Cases
Takenami, T., Tsujinaka, S., Takahashi, J. A., Tamaki, S., Maemoto, R., Fukuda, R., Ishikawa, H., Kakizawa, N., Hasegawa, F., Kikugawa, R., et al. (2019) · Case Reports in Surgery · doi:10.1155/2019/8129358 · Cited by 3
An Evaluation of RAS Testing Among Metastatic Colorectal Cancer Patients in the USA
Sangaré, L. R., Delli-Zotti, K. A., Florea, A., Rehn, M., Benson, A. B., & Lowe, K. A. (2021) · Future Oncology · doi:10.2217/fon-2020-1075 · Cited by 3
Erratum to: Role of family history and tumor location on prognosis of patients with colorectal cancer and synchronous metastases
Colloca, G. A., & Venturino, A. (2017) · International Journal of Colorectal Disease · doi:10.1007/s00384-017-2877-6 · Cited by 3
Cetuximab or Bevacizumab With First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer
Lieu, C. H., & Messersmith, W. A. (2017) · JAMA · doi:10.1001/jama.2017.6673 · Cited by 3
Fusobacterium nucleatum facilitates cetuximab resistance in colorectal cancer via the PI3K/AKT and JAK/STAT3 pathwaysPreprint
Han, H., Li, Y., Qin, W., Wang, L., Yin, H., Su, B., & Yuan, X. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.21.423755 · Cited by 3
A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial
Liu, R., Yin, X., Bai, Y., Zhong, H., Ye, F., Wang, Q., Liu, M., Li, N., Deng, Y., Wang, Y., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115566 · Cited by 2
Evaluation of the efficacy of regorafenib treatment by location and RAS mutation in metastatic colon cancer
Ata, S., Gülmez, A., Köşeci, T., Özalp, Ö., Çil, T., & Duman, B. B. (2025) · Medicine · doi:10.1097/md.0000000000042897 · Cited by 2
Left Versus Right: Does Location Matter for Refractory Metastatic Colorectal Cancer Patients in Phase 1 Clinical Trials?
Arora, S. P., Ketchum, N. S., Michalek, J. E., Gelfond, J. A. L., & Mahalingam, D. (2017) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-017-9948-3 · Cited by 2
Detection of therapeutically relevant and concomitant rare somatic variants in colorectal cancer
Mikolajčík, P., Lasabová, Z., Loderer, D., Grendár, M., Kalman, M., Kašubová, I., Lučanský, V., Wiederhold, A. J., Marcinek, J., Burjanivová, T., et al. (2021) · Neoplasma · doi:10.4149/neo_2021_210616n804 · Cited by 2
Kolorektale Karzinome: Die Lage des Primarius zählt
Siegmund-Schultze, N. (2017) · Deutsches Ärzteblatt · doi:10.3238/personko/2017.02.03.05 · Cited by 2
Embryologic Origin of the Primary Tumor and RAS Status Predict Survival after Resection of Colorectal Liver Metastases
Alexandrescu, S. T., Dinu, I. M., Diaconescu, A.-S., Micu, A., Pasare, E., Durdu, C.-E., Dorobanţu, B., & Popescu, I. (2022) · Medicina · doi:10.3390/medicina58081100 · Cited by 2
Evaluation of Overall Survival Rate of Patients with Metastatic Colorectal Cancer Depending on Choice of Treatment, Location of Primary Focus and RAS Genes Mutation Status
Shiryaev, N. P., Валентинович, Ч. С., Николаевич, М. В., Андреевна, К. Ю., Евгеньевна, А. А., & Валерьевна, М. В. (2023) · I P Pavlov Russian Medical Biological Herald · doi:10.17816/pavlovj108986 · Cited by 2
Second-line treatment strategies for RAS wild-type colorectal cancer: A systematic review and Network Meta-analysis (NMA)
Nardo, P. D., Basile, D., Siciliano, A., Pelizzari, G., Corvaja, C., Buriolla, S., Ongaro, E., Grazia, D. M., Garattini, S. K., Foltran, L., et al. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.07.013 · Cited by 3
Development and validation of prognostic nomograms for early-onset colon cancer in different tumor locations: a population-based study
Zhu, S., Tu, J., Pei, W., Zheng, Z., Bi, J., & Feng, Q. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02991-1 · Cited by 3
Sidedness is not a prognostic factor in an unselected cohort of patients with colon cancer but prognosis for caecal carcinoma is worse – A multivariate analysis of a large single institution database
Stelzner, S., Mehdorn, M., Puffer, E., Bleyl, D., Kittner, T., Rhode, P., Gockel, I., & Mees, S. T. (2024) · International Journal of Colorectal Disease · doi:10.1007/s00384-023-04590-8 · Cited by 2
Unraveling the role of tumor sidedness in prognosis of stage II colon cancer
Yang, Y. S., Yang, X., Bai, Z., Gu, X., Shah, S. R., Salewala, K. S., Kevadiya, M. P., & Zhang, Z. (2023) · Gastroenterology report · doi:10.1093/gastro/goae028 · Cited by 2
Expression of Human Endogenous Retrovirus Env Gene Product Is a Hallmark of Sidedness in Operable Colorectal Cancer
Dolci, M., Civettini, I., Bagnoli, P. F., Toumi, W., Signorini, L., Crocchiolo, R., Maina, K. K., Perego, F., Ferrante, P., Scagnolari, C., et al. (2025) · Oncology · doi:10.1159/000543099 · Cited by 2
Frontline Strategies for Metastatic Colorectal Cancer: New Sides to the Story
King, G. T. (2017) · American Journal of Hematology / Oncology® · Cited by 2
BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?
Wong, V., Lee, M., Wong, R., Tie, J., Shapiro, J. D., Desai, J., Nott, L. M., Steel, S. A., Burge, M., Ma, B. B. Y., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00793-7 · Cited by 2
Anti-EGFR and Anti-VEGF Agents in First-Line Therapy for Advanced Colorectal Cancer
Mitchell, A. P., & Sanoff, H. K. (2017) · Current Colorectal Cancer Reports · doi:10.1007/s11888-017-0372-7 · Cited by 2
Colorectal cancer treatment: An introduction
Juretić, A., Juretić, A., Froebe, A., Đaković, N., Marić-Brozić, J., Šantek, F., & Beketić-Orešković, L. (2017) · Rad Hrvatske akademije znanosti i umjetnosti Medicinske znanosti · doi:10.21857/94kl4cwkzm · Cited by 2
The Interference between Oxaliplatin & anti-EGFR Therapies: A Different Hypothesis to Explain the ‘Unexplainable’
Basso, M., Dadduzio, V., Rossi, S., D’Argento, E., Strippoli, A., Salvatore, M. D., Orlandi, A., Zurlo, I. V., Noia, V. D., & Barone, C. A. (2018) · Personalized Medicine · doi:10.2217/pme-2017-0082 · Cited by 2
The Significance of Sidedness in Patients with Metastatic Colorectal Cancer Treated with Triplet First-line Chemotherapy
Bazarbashi, S. N., Omar, A., Raddaoui, L., Badran, A. A., Alzahrani, A., Aljubran, A. H., & Elhassan, T. A. M. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.10.2891 · Cited by 2
The prognostic factors of primary colorectal sarcoma and the clinical outcomes of negative lymph node dissection
Wei, Z., Mao, R., Zhang, Y., Bi, X., Zhou, J., Li, Z., Huang, Z., Chen, X., Zhao, J., Zhao, H., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4286 · Cited by 2
Pharmacotherapy for unresectable metastatic colorectal cancer
Rogers, J. E., & Dasari, A. N. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1982895 · Cited by 2
Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy—Analysis of the Phase 3 XELAVIRI Trial
Kurreck, A., Heinemann, V., von Weikersthal, L. F., Decker, T. W., Kaiser, F., Uhlig, J., Schenk, M., Freiberg‐Richter, J., Peuser, B., Denzlinger, C., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.751453 · Cited by 2
Self-citation
The Phase II Study of Panitumumab in Chemotherapy-Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer: OGSG 1602 Final Results
Terazawa, T., Kato, T., Goto, M., Ohta, K., Satake, H., Noura, S., Kagawa, Y., Kawakami, H., Hasegawa, H., Yanagihara, K., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac145 · Cited by 2
Primary tumor location and survival among metastatic colorectal cancer patients treated with systemic chemotherapy and biologic therapies: Retrospective analysis
Ramadan, M. M., Alfayea, T. M., Alsofyani, A. A., Alzahrani, M., Alyabsi, M., AlHusseini, D. N., & Algarni, A. S. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100632 · Cited by 4
Regorafenib therapy as a third-line treatment for metastatic colorectal cancer: A single center long term experience
Özkan, M., Oflazoğlu, U., Yıldız, Y., Güç, Z. G., Salman, T., Ünal, S., Küçükzeybek, Y., & Alacacıoğlu, A. (2023) · Medicine · doi:10.1097/md.0000000000036435 · Cited by 2
TACE in colorectal liver metastases – different outcomes in right-sided and left-sided primary tumour location
Seidl, S., Bischoff, P., Schaefer, A., Esser, M., Janzen, V., & Kovács, A. (2020) · Integrative Cancer Science and Therapeutics · doi:10.15761/icst.1000328 · Cited by 2
Prognostic Impact of Tumor Status, Nodal Status and Tumor Sidedness in Metastatic Colon Cancer
Mukkamalla, S. K. R., Somasundar, P. S., & Rathore, B. (2020) · Cureus · doi:10.7759/cureus.11444 · Cited by 2
Does Sidedness Matter in Unresectable Colorectal Cancer?
Kamath, S. D., & Khorana, A. A. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07315-w · Cited by 2
Reply to C. Kersten et al and D.A. Parikh et al
Qin, S., Liu, T., & Li, J. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02369 · Cited by 2
Primary Tumor Location and Survival Among Metastatic Colorectal Cancer Patients treated with systemic chemotherapy, and biologic therapies: Retrospective Analysis (2013-2016)Preprint
Ramadan, M. M., Alfayea, T. M., Alsofyani, A. A., Alzahrani, M., Alyabsi, M. S., Alhusseini, N. K., & Algarni, A. S. (2022) · Research Square · doi:10.21203/rs.3.rs-1387467/v1 · Cited by 2
Molecular Diagnostics and Genomic Profiling in Individualized Therapies of Gastrointestinal Cancers
Kamgar, M., & Korn, W. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-18890-0_34 · Cited by 1
Therapie kolorektaler und nichtkolorektaler Lebermetastasen: Sinnhaftigkeit neoadjuvanter Therapiekonzepte
Gül‐Klein, S., Schmuck, R. B., Modest, D. P., & Pratschke, J. (2020) · Der Chirurg · doi:10.1007/s00104-020-01133-7 · Cited by 1
Demographic Profile and Clinicopathological Patterns of Colorectal Cancer in Subhimalayan North India
Gupta, N., Verma, S., Negi, M. K., & Devi, S. (2021) · Bengal Journal of Cancer · doi:10.4103/bjoc.bjoc_18_21 · Cited by 1
Initial Systemic Chemotherapy for Metastatic Colorectal Cancer
Yu, I. S., Advani, S., & Kopetz, S. (2022) · Springer eBooks · doi:10.1007/978-3-031-09323-4_31 · Cited by 1
Targeted Therapy in the Palliative Setting of Colorectal Cancer—Survival and Medical Costs
Inci, K., Nilsson, B., Ny, L., Strömberg, U., Wilking, N. E., LINDSKOG, S., & Giglio, D. (2023) · Cancers · doi:10.3390/cancers15113022 · Cited by 1
Impact of Primary Tumor Location on Demographics, Resectability, Outcomes, and Quality of Life in Finnish Metastatic Colorectal Cancer Patients (Subgroup Analysis of the RAXO Study)
Aho, S., Österlund, E., Ristimaki, A. P., Nieminen, L., Sundström, J. T. T., Mäkinen, M. J., Kuopio, T., Kytölä, S. I., Ålgars, A., Ristamäki, R., et al. (2024) · Cancers · doi:10.3390/cancers16051052 · Cited by 1
Toward optimizing patient selection for EGFR antibody therapies in metastatic colorectal cancer: outcomes and resistance features in real-world data
Emmett, M. J., Quintanilha, J. C. F., Graf, R. P., Li, G., Tukachinsky, H., Schrock, A. B., Morley, S., Fisher, V. A., Oxnard, G. R., Lieu, C. H., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100036 · Cited by 1
Explanatory Role of Conversion Surgery as a Mediator of the Mortality Risk Difference Between Patients With Unresectable Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR Agents Versus Bevacizumab
Su, C., Su, Y., Wu, C., & Lee, P.-T. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.05.008 · Cited by 1
Successful cetuximab rechallenge in metastatic colorectal cancer: A case report
Guedes, A., Silva, S., Custódio, S., & Capela, A. (2024) · World Journal of Clinical Oncology · doi:10.5306/wjco.v15.i9.1232 · Cited by 1
Treatment of stage IV colorectal cancer: A retrospective cohort study assessing whether failure of first‑line treatment indicates failure of second‑line treatment
Peyerl, H., Kreye, G., Pecherstorfer, M., & Singer, J. (2024) · Molecular and Clinical Oncology · doi:10.3892/mco.2024.2805 · Cited by 1
Molecular biomarkers for predicting complete response to preoperative chemoradiation in people with locally advanced rectal cancer
Lacavalerie, P. D., Lord, S. J., Morgan, M. J., Caldon, C. E., & Kohonen‐Corish, M. R. J. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014718 · Cited by 1
Homologous recombination deficiency and immunotherapy response in microsatellite-stable colorectal cancer: Evidence from a cohort study in China
Feng, H., Zhao, L., Xu, Z., Xie, Q.-F., Deng, H., Jiang, Y., & Liu, H. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i5.102767 · Cited by 2
Consensus Statements for Clinical Practice in Advanced/Metastatic Colorectal Cancers in India Using a Modified Delphi Method
Ramaswamy, A., Srinivas, S., Lavingia, V. K., Boppana, M., Vora, C., Singh, R., Krishna, M. V., Vora, A., Mullapally, S. K., BHARGAVA, P. G., et al. (2025) · South Asian Journal of Cancer · doi:10.1055/s-0045-1809380 · Cited by 1
Simultaneous double primary malignant tumors of MSS/pMMR ascending colon cancer and MSI-H/dMMR duodenal cancer with nearly 2 years of recurrence-free survival after MDT-guided comprehensive treatment: a case report
Wang, W., Yang, Q., He, Y., Cha, X., Xiong, C., Li, M., Li, J., Gao, P., & Yu, K. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1573580 · Cited by 2
Second-Line Treatment Strategies for Right-Sided, RAS/RAF Wild-Type Colorectal Cancer
Swami, N. S., Hwang, W., Mamtani, R., O’Hara, M. H., & Chapin, W. J. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.15087 · Cited by 1
Confounder-Adjusted Differentiation of Colorectal Cancer via Dynamic Propagation of Pathway Influence
Batrancea, L. M., Akgüller, Ö., Balcı, M. A., Calibasi‐Kocal, G., & Gãban, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010023 · Cited by 1
Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Gerritse, S. L., Helden, E. J. V., Arens, A. I. J., Boellaard, R., Buffart, T. E., Labots, M., Angus, L., de Vries, E. G. E., de Groot, D. J., Pruijt, H. F. M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1768 · Cited by 1
Clinicopathological predictors of right para esophageal lymph node metastasis in papillary thyroid carcinoma: A systematic review and meta-analysis
Khawar, M. M. H., Abid, M. H., Cheema, M. B. A., Khawar, M., Shaukat, M., Khan, M. H. A., Saifullah, M., Noureen, R., Khail, H. A., Qureshi, A. A., et al. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i11.110792 · Cited by 1
An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development
Chamseddine, S., Azmi, A. S., & Saif, M. W. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2611395 · Cited by 2
A multicenter, placebo-controlled clinical trial and preliminary experimental study exploring the efficacy of modified Banxia Xiexin Decoction in the treatment of advanced colorectal cancer
Wu, Z., Li, X., Xiao, C., You, F., & Su, L. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121292 · Cited by 2
Research progress of small molecule protein kinase inhibitors (SMKIs) in the treatment of colorectal cancer: mechanism, application, and future prospects
Liu, L., 陈颖君, Guo, M., Yun, F., Li, X., Chen, L., Li, Y. M., & Li, F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1782130 · Cited by 1
Conversion Therapy for Initially Borderline/Unresectable Metastases in Colon Cancer: What Is the Best Neoadjuvant Chemotherapy?
Haraldsdóttir, S., & Goldberg, R. M. (2017) · Current Colorectal Cancer Reports · doi:10.1007/s11888-017-0393-2 · Cited by 1
Colorectal Cancers Developed from Proximal and Distal Tumor Location Belong to the Distinct Genetic Entity and Show Different Oncologic Behavior
Matsubara, N. (2017) · Current human cell research and applications · doi:10.1007/978-981-10-6469-2_5 · Cited by 1
ASO Author Reflections: Primary Tumor Location and Long-Term Survival After Hepatic Resection for Metastatic Colon Cancer
Creasy, J. M., & D'Angelica, M. I. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6918-3 · Cited by 1
Treatment choices in metastatic colorectal cancer according to sidedness and RAS/BRAF status: a national survey by the Brazilian Gastrointestinal Tumors Group (GTG)
Peixoto, R. D., Riechelmann, R. P., Prolla, G., Weschenfelder, R. F., Fernandes, G. D. S., Pereira, G. S., de-Oliveira, M. D. L., Rego, J. F., Rocha-Filho, D. R., & Coutinho, A. K. (2019) · Brazilian Journal of Oncology · doi:10.5935/2526-8732.20190021 · Cited by 1
Podtypy molekularne raka jelita grubego jako potencjalny czynnik prognostyczny i predykcyjny przy wyborze optymalnej strategii leczenia.
Frąckowiak, M., Lewandowski, T., & Stelmasiak, P. (2020) · Oncology in Clinical Practice · doi:10.5603/ocp.2019.0036 · Cited by 1
Emerging Treatment Options for the Management of Metastatic Colorectal Cancer
Deming, D. A. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.5016 · Cited by 1
Systemic chemotherapy combined with anti-epidermal growth factor receptor antibody therapy for RAS wild-type appendiceal signet-ring cell carcinoma: a series of three cases
Hirose, S., Enami, C., Kawamatsu, N., Yoshimi, I. T. O., Onoda, T., Sugiyama, Y., Suzuki, H., Nagafuchi, M., Ikeda, T., Niisato, Y., et al. (2021) · International Cancer Conference Journal · doi:10.1007/s13691-021-00507-w · Cited by 1
Oncologic aspects of the decision-making process for surgical approach for colorectal liver metastases progressing during chemotherapy
Araújo, R. L. C., Carvalho, C. G. C. Y., Maeda, C. T., Milani, J. M., Bugano, D. D. G., de Moraes, P. H. Z., & Linhares, M. M. (2022) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v14.i9.877 · Cited by 2
Real-Life Experience of the Prognostic Significance of the Primary Tumor Location on the Timing of Colorectal Liver Metastases: A Retrospective Analysis
Signorelli, C., Amodio, P. M., Chilelli, M. G., Santoro, R., Schirripa, M., Ranalli, T. V., Pessina, G., Berrìos, J. R. G., Natoni, F., Virtuoso, A., et al. (2022) · Cureus · doi:10.7759/cureus.30607 · Cited by 1
A study of gene variation in All-RAS wild-type metastatic colorectal cancer and its correlation with cetuximab
Tao, H., Shen, M., Zhang, X., Wang, M., Wu, Y., Sun, H., Chen, L., Yang, Y., Chen, K., & Li, D. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-1237 · Cited by 1
Metastasiertes kolorektales Karzinom – moderne Therapiestrategien und -sequenzen
Ettrich, T. J., Schuhbaur, J., & Seufferlein, T. T. W. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01516-y · Cited by 1
Prediction of death probability in adenocarcinoma of the transverse colon: competing-risk nomograms based on 21,469 patients
Su, H., Wang, S., Xie, S., Huang, L., Pan, Y.-L., & Lyu, J. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04913-w · Cited by 1
The Prognostic Significance of Laterality in Endoscopically Resected Colonic Adenomas With High-Grade Dysplasia
Boatman, S. M., Kohn, J. F., Mott, S. L., Marmor, S., Madoff, R. D., Gaertner, W. B., Shaukat, A., Melton, G. B., Hassan, I., & Goffredo, P. (2023) · Techniques and Innovations in Gastrointestinal Endoscopy · doi:10.1016/j.tige.2023.07.003 · Cited by 1
Palliative resection of the primary tumour improves survival in incurable metastatic colorectal cancer
Inci, K., Nilsson, B., Lyckenblad, K., LINDSKOG, S., & Giglio, D. (2023) · ANZ Journal of Surgery · doi:10.1111/ans.18629 · Cited by 1
oss of CDX2 and high COX2 (PTGS2) expression in metastatic colorectal cancer
Caldas, Á. M. C., Nunes, W. A., Taboada, R. G., Cesca, M. G., Germano, J. N., & Riechelmann, R. P. (2024) · ecancermedicalscience · doi:10.3332/ecancer.2024.1666 · Cited by 1
Optimising treatment strategies in metastatic colorectal cancer: insights from CAIRO4
Guzel, H. G., İlhan, Y., & Önder, A. H. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.10.004 · Cited by 1
The Role of Gut Microbiota in Tumor Recurrence and Therapy Resistance in Colorectal Cancer: Molecular Mechanisms and Clinical Implications
do Rêgo, A. C. M., & Araújo-Filho, I. (2025) · Japan Journal of Research · doi:10.33425/2690-8077.1173 · Cited by 1
Effects of location of primary tumor on survival after pulmonary metastasectomy for colorectal cancer
Putatunda, V., Hernandez, F., Freidlin, M. J., Hoang, C. D., Hernandez, J. M., & Carr, S. R. (2025) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2025.101954 · Cited by 1
Real-World Evidence for Comparative Outcomes between Innovator and Biosimilar Bevacizumab in Advanced Colorectal Cancers
Vaidyanathan, A., Vana, P., Joshi, N., Sourav, B., BHARGAVA, P. G., John, G., Ramaswamy, A., & Ostwal, V. S. (2024) · South Asian Journal of Cancer · doi:10.1055/s-0045-1804535 · Cited by 1
Genomic profiling of colorectal cancers and the future of personalized treatment
Harada, K., Kaya, D. M., Song, S., Baba, H., & Ajani, J. A. (2017) · Colorectal Cancer · doi:10.2217/crc-2016-0017 · Cited by 1
Molekulare Stratifizierung von kolorektalen Karzinomen – was hat Relevanz für die klinische Praxis?
Stintzing, S., & Modest, D. P. (2018) · TumorDiagnostik & Therapie · doi:10.1055/s-0043-120711 · Cited by 1
Self-citation
Report from the 19th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29–30 September 2017
Kim, C., Ahmed, S., Ahmed, S., Brunet, B., Chalchal, H. I., Deobald, R. G., Döll, C., Dupre, M. P., Gordon, V., Lee‐Ying, R. M., et al. (2018) · Current Oncology · doi:10.3747/co.25.4109 · Cited by 1
Prognostic importance of primary tumor location in RAS mutant metastatic colorectal cancer
Akdeniz, N., Ma, K., Küçüköner, M., Urakçı, Z., Sezgin, Y., Ebinç, S., Bilen, E., Karhan, O., Laçin, Ş., Büyükbayram, H., et al. (2019) · Dicle Medical Journal / Dicle Tip Dergisi · doi:10.5798/dicletip.539998 · Cited by 1
Metastatik Kolorektal Kanserli Hastaların RAS Mutasyon Durumuna Göre Klinik ve Patolojik Özellikleri
Sezen, M., & Araz, M. (2019) · Uludağ Üniversitesi Tıp Fakültesi Dergisi · doi:10.32708/uutfd.524758 · Cited by 1
ASO Author Reflections: Prognostic Impact of Primary Tumor Sidedness for Unresectable Stage IV Colorectal Cancer
Shida, D. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07666-4 · Cited by 1
Onkologische Therapiekonzepte bei systemischer Metastasierung des kolorektalen Karzinoms
Modest, D. P., & von Bergwelt‐Baildon, M. (2019) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-0895-6007 · Cited by 1
Report from the 20th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; 28–29 September 2018
Le, D., Ahmed, S., Ahmed, S., Brunet, B., Davies, J. M., Döll, C., Ferguson, M., Ginther, N., Gordon, V., Hamilton, T. D., et al. (2019) · Current Oncology · doi:10.3747/co.26.5517 · Cited by 1
Long-term treatment response on therapy trifluridin/tipiracil (Lonsurf®) in patient with metastatic colorectal cancer
Stuhlová, Š. (2020) · Onkologie · doi:10.36290/xon.2020.040 · Cited by 1
Biomarkers in colon cancer and its clinical implications
Pavithran, K., & Srinivasalu, V. K. (2020) · Journal of Current Oncology · doi:10.4103/jco.jco_38_20 · Cited by 1
Application and Progress of Targeted Drug Therapy for Colorectal Cancer
严, 双. (2021) · World Journal of Cancer Research · doi:10.12677/wjcr.2021.111004 · Cited by 1
Is the Effect of Tumor Localization on Prognosis Compatible with Real-life Data in Metastatic Colon Cancer? Single-Center Experience: A Retrospective Analysis
Güner, M., Bulut, G., & Gökmen, E. (2021) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-021-00615-z · Cited by 1
Znaczenie kliniczne umiejscowienia ogniska pierwotnego raka jelita grubego
Janiak, A., Połowinczak-Przybyłek, J., Czyżykowski, R. Ł., & Potemski, P. (2021) · Oncology in Clinical Practice · doi:10.5603/ocp.2020.0043 · Cited by 1
Modern strategy for treatment of metastatic colorectal cancer as key to increasing life expectancy of patients with metastatic colorectal cancer without mutations in RAS genes
Артамонова, Е. В. (2021) · Medical alphabet · doi:10.33667/2078-5631-2021-19-54-63 · Cited by 1
Hepatisch metastasiertes kolorektales Karzinom
Ettrich, T. J., Hüttner, F. J., Lisson, C. G., Gani, C., Prasad, V., & Seufferlein, T. T. W. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1391-5273 · Cited by 1
A Case of Rectosigmoid Colon Cancer with Tumor Thrombus in the Inferior Mesenteric Vein
Toyofuku, A., KOREEDA, Y., Yugo, I. H. A., Yoshida, K., Higure, A., Sasaguri, T., & Nagata, N. (2021) · Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) · doi:10.3919/jjsa.82.1550 · Cited by 1
Colon Cancer
Polite, B. N. (2019) · Springer eBooks · doi:10.1007/978-3-030-31471-2_7 · Cited by 1
Role of Biologics in Colon Cancer: Still Not Clear
Atreya, C. E., & Venook, A. P. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.018697 · Cited by 1
Response to letter entitled: Distinct metastatic patterns in colorectal cancer patients
Holch, J. W., & Heinemann, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.022 · Cited by 1
Self-citation
Whose side are you on?
Taı̈eb, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx270 · Cited by 1

Authors: Tejpar, S., Stintzing, S., Ciardiello, F., Tabernero, J., Van Cutsem, E., Beier, F., Esser, R., Lenz, H.-J., & Heinemann, V.
Affiliations: Universitair Ziekenhuis Leuven (BE)
Ludwig-Maximilians-Universität München (DE)
University of Campania "Luigi Vanvitelli" (IT)
Universitat Autònoma de Barcelona (ES)
Digestive Oncology, University Hospitals Leuven and KULeuven, Leuven, Belgium
Merck KGaA, Darmstadt (Germany) (DE)
University of Southern California (US)
Corresponding author: Tejpar, Sabine
ORCID: Tejpar, Sabine
Stintzing, Sebastian
Ciardiello, Fortunato
Tabernero, Josep
Beier, Frank
Esser, Regina
Lenz, Heinz-Josef
Heinemann, Volker
Venue: JAMA Oncology
Publisher: American Medical Association (AMA)
Published: 2017-02-01
Volume: 3
Issue: 2
Pages: 194
ISSN: 2374-2437 (ISSN-L)
DOI: 10.1001/jamaoncol.2016.3797
PMC: PMC7505121
OpenAlex: W2531319683
Cited by: 709
References: 24
Citations by year: 2026: 19 · 2025: 35 · 2024: 64 · 2023: 48 · 2022: 70 · 2021: 89 · 2020: 85 · 2019: 97 · 2018: 102 · 2017: 96
FWCI: 53.50
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: JAMA Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Funders: National Cancer Institute (P30CA014089)
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: metastatic colorectal cancer, RAS wild-type, primary tumor site, cetuximab, FOLFIRI, bevacizumab, first-line therapy, progression-free survival, overall survival, objective response rate, predictive biomarkers, CRYSTAL trial, FIRE-3 trial, EGFR inhibition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks